For updates visit


Indian Stock Market


Sun Pharmaceutical receives "will-not-sue" covenant on generic Effexor XR ANDA

Wednesday, October 17, 2007

Sun Pharmaceutical Industries has announced receipt of a Covenant Not to Sue from Wyeth over Sun Pharma’s Abbreviated New Drug Application (ANDA) for generic venlafaxine extended release tablets with multiple para IV certifications, according to a BSE notice.

This ANDA for generic venlafaxine extended release tablets, AB-rated equivalent of Wyeth’s Effexor XR® Capsules, includes three strengths: 37.5 mg, 75 mg and 150 mg and is based on Innovative technology for extended release tablets. These strengths of Effexor XR® Capsules have annual sales approximately USD 2.6 billion in the US.

As per the covenant, Wyeth covenants not to sue Sun under any claims of US Patent Nos. 6,274,171, 6,4013,120 and 6,419,958. Venlafaxine is an antidepressant of the serotonin-noreplnephrine reuptake inhibitor (SNRI) class

Posted by FR at 9:04 AM  

Catagories

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

IMPORTANT DISCLAIMER

Investment in equity shares has its own risks. Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that we consider reliable. I, however, do not vouch for the accuracy or the completeness thereof. This material is for personal information and I am not responsible for any loss incurred based upon it.& take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations given in this blog.